DOI QR코드

DOI QR Code

Lack of Association Between the Matrix Metalloproteinase-2 -1306C>T Polymorphism and Breast Cancer Susceptibility: a Meta-analysis

  • Yang, Lu (Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine) ;
  • Li, Ning (Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine) ;
  • Wang, Siyu (Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine) ;
  • Kong, Yanan (Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine) ;
  • Tang, Hailin (Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine) ;
  • Xie, Xinhua (Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine) ;
  • Xie, Xiaoming (Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine)
  • Published : 2014.06.30

Abstract

Background: Since inconsistent results have been reported regarding the relation between the matrix metalloproteinase-2 (MMP-2) -1306C>T polymorphism and susceptibility for breast cancer, we performed a meta-analysis to investigate the issue. Materials and Methods: An internet search of PubMed and EMBASE was performed to identify eligible studies. Pooled odds ratios (ORs) with their corresponding confidence intervals (CIs) were calculated to evaluate any association between MMP-2 -1306C>T polymorphism and breast cancer susceptibility. Results: Nine case-control studies were included in the meta-analysis, involving 9,858 cases and 10,871 controls. Overall, there was no evidence of any association between the MMP-2 -1306C>T polymorphism and breast cancer susceptibility in different genetic models (T-allele vs C-allele: OR=0.95, 95%CI, 0.82-1.10, p=0.49; TT vs CC: OR=1.03, 95%CI, 0.90-1.19, p=0.66; TT+TC vs CC: OR=0.93, 95%CI, 0.78-1.10, p=0.38; TT vs TC+CC: OR=1.02, 95%CI, 0.89-1.17, p=0.77). In the subgroup analysis by ethnicity, CC was associated with a significant increase in breast susceptibility among Latin-Americans in the dominant model (OR=0.61, 95%CI, 0.40-0.93, p=0.02), but the association disappeared in other models. No significant association was observed among Europeans, East Asians and others in different genetic models. In the subgroup analysis by their source of controls, no significant association between MMP-2 -1306C>T polymorphism and breast cancer susceptibility was noted among population-based studies and hospital-based studies in different genetic models. Conclusions: The results of this meta-analysis suggest that MMP-2 -1306C>T polymorphism is not associated with breast cancer susceptibility, although the association among Latin-Americans in the dominant model was significant.

References

  1. Zhou Y, Yu C, Miao X, et al (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis, 25, 399-404.
  2. Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-28. https://doi.org/10.1158/0008-5472.CAN-04-1521
  3. Zagouri F, Sergentanis TN, Gazouli M, et al (2013). MMP-2-1306C>T polymorphism in breast cancer: a case-control study in a South European population. Mol Biol Rep, 40, 5035-40. https://doi.org/10.1007/s11033-013-2604-5
  4. Zhou P, Du LF, Lv GQ, et al (2011). Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 127, 813-18. https://doi.org/10.1007/s10549-010-1294-0
  5. Saeed HM, Alanazi MS, Alshahrani O, et al (2013a). Matrix metalloproteinase-2 CT promoter polymorphism and breast cancer risk in the Saudi population. Acta Biochim Pol, 60, 405-09.
  6. Peng B, Cao L, Ma X, et al (2010). Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis, 25, 371-79. https://doi.org/10.1093/mutage/geq015
  7. Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58. https://doi.org/10.1074/jbc.M010242200
  8. Roehe AV, Frazzon AP, Agnes G, et al (2007). Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat, 102, 123-24. https://doi.org/10.1007/s10549-006-9273-1
  9. Saeed HM, Alanazi MS, Parine NR, et al (2013b). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the Saudi population. Asian Pac J Cancer Prev, 14, 6025-30. https://doi.org/10.7314/APJCP.2013.14.10.6025
  10. Silva Idos S, De Stavola B, McCormack V (2008). Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Med, 5, 193. https://doi.org/10.1371/journal.pmed.0050193
  11. Slattery ML, John E, Torres-Mejia G, et al (2013). Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PloS one, 8, 63165. https://doi.org/10.1371/journal.pone.0063165
  12. Stamenkovic I (2000). Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol, 10, 415-33. https://doi.org/10.1006/scbi.2000.0379
  13. Yadav L, Puri N, Rastogi V, et al (2014). Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085-91. https://doi.org/10.7314/APJCP.2014.15.3.1085
  14. Lei H, Hemminki K, Altieri A, et al (2007). Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat, 103, 61-69. https://doi.org/10.1007/s10549-006-9345-2
  15. Hulka BS, Moorman PG (2001). Breast cancer: hormones and other risk factors. Maturitas, 38, 103-13. https://doi.org/10.1016/S0378-5122(00)00196-1
  16. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  17. Ledwon JK, Hennig EE, Maryan N, et al (2013). Common low-penetrance risk variants associated with breast cancer in Polish women. BMC Cancer, 13, 510. https://doi.org/10.1186/1471-2407-13-510
  18. Li Y, Sun DL, Duan YN, et al (2010). Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep, 37, 197-205. https://doi.org/10.1007/s11033-009-9593-4
  19. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  20. McColgan P, Sharma P (2009). Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer, 125, 1473-78. https://doi.org/10.1002/ijc.24441
  21. Miao X, Yu C, Tan W, et al (2003). A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res, 63, 3987-90.
  22. Nagase H, Woessner JF, Jr. (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-94. https://doi.org/10.1074/jbc.274.31.21491
  23. O'Shaughnessy J (2005). Extending survival with chemotherapy in metastatic breast cancer. Oncologist, 10, 20-29. https://doi.org/10.1634/theoncologist.10-90003-20
  24. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-1101. https://doi.org/10.2307/2533446
  25. Baan R, Straif K, Grosse Y, et al (2007). Carcinogenicity of alcoholic beverages. Lancet Oncol, 8, 292-93. https://doi.org/10.1016/S1470-2045(07)70099-2
  26. Baker EA, Stephenson TJ, Reed MW, Brown NJ (2002). Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol, 55, 300-04 https://doi.org/10.1136/mp.55.5.300
  27. Beeghly-Fadiel A, Lu W, Long JR, et al (2009). Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 18, 1770-76. https://doi.org/10.1158/1055-9965.EPI-09-0125
  28. Brummer O, Athar S, Riethdorf L, Loning T, Herbst H (1999). Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch, 435, 566-73. https://doi.org/10.1007/s004280050442
  29. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al (2008). Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest, 65, 68-72. https://doi.org/10.1159/000108282
  30. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  31. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  32. Garbett EA, Reed MW, Brown NJ (1999). Proteolysis in human breast and colorectal cancer. Br J Cancer, 81, 287-93. https://doi.org/10.1038/sj.bjc.6690689
  33. Grieu F, Li WQ, Iacopetta B (2004). Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat, 88, 197-204. https://doi.org/10.1007/s10549-004-0595-6
  34. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557

Cited by

  1. Matrix Metalloproteinase-2 -1306 C>T Gene Polymorphism is Associated with Reduced Risk of Cancer: a Meta-analysis vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.889
  2. Expression of RECK and MMPs in Hepatoblastoma and Neuroblastoma and Comparative Analysis on the Tumor Metastasis vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4007
  3. Associations of MMP-2 −1306 C/T and MMP-9 −1562 C/T polymorphisms with breast cancer risk among different populations: a meta-analysis vol.39, pp.3, 2017, https://doi.org/10.1007/s13258-016-0498-z